Dermatology · Fargo, ND
Dermatology and skin studies in Fargo, ND
10 recruiting studies have a site in Fargo.
10 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Sanofi
- Location
- Fargo, ND + 17 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
Pfizer
- Location
- Fargo, ND + 7 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 1
Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc.
- Location
- Fargo, ND + 8 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
Sanofi
- Location
- Fargo, ND + 14 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 1
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Incyte Corporation
- Location
- Fargo, ND + 15 other US sites
- Eligibility basics
- Ages 12–75
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation
- Location
- Fargo, ND + 65 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 2
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Apollo Therapeutics Ltd
- Location
- Fargo, ND + 24 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Inmagene LLC
- Location
- Fargo, ND + 15 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 1
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
LAPIX Therapeutics Inc.
- Location
- Fargo, ND + 1 other US site
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
SFA Therapeutics
- Location
- Fargo, ND + 2 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.